A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

152

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

November 11, 2026

Study Completion Date

February 11, 2027

Conditions

Geographic Atrophy

Interventions

DRUG

BRX011

Subjects will ingest BRX011 orally, as capsules.

DRUG

Placebo

Subjects will ingest Placebo orally, as capsules.

All Listed Sponsors

lead

Biojiva LLC

INDUSTRY